PROX1 and cholangiocarcinoma: IHC and IF experiments were performed, and the results showed that the expression distribution of PROX-1, PDPN, and LYVE-1 basically overlapped, indicating that PDPN and LYVE-1 are suitable as lymphatic markers for CCA Supplementary (Fig. 4A-C).